Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
A combination allergen extract containing both house dust mite and Alternaria (a common mold) extracts, used in allergen immunotherapy for the treatment of allergic diseases such as allergic rhinitis or asthma. This therapy works by gradually exposing the immune system to small, controlled amounts of these allergens to induce tolerance and reduce symptoms over time. The mechanism involves modulation of the immune response, shifting from an IgE-mediated hypersensitivity reaction toward a more regulated or tolerant state. This combination is typically administered as part of allergy shots (subcutaneous immunotherapy) or custom-mixed sublingual drops/tablets prepared by allergists for patients with confirmed sensitivities to both allergens[3][6][8]. House dust mite and Alternaria are among the most common indoor allergens implicated in perennial allergic rhinitis and asthma.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on house dust mite + alternaria extract.